The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy.

Xie, Xin; Lv, Jingwen; Zhu, Wei; Tian, Chao; Li, Jingfeng; Liu, Jiajia; Zhou, Hua; Sun, Chunyang; Hu, Zongfeng; Li, Xiaopeng

Xie, Xin; Lv, Jingwen; Zhu, Wei; Tian, Chao; Li, Jingfeng; Liu, Jiajia; Zhou, Hua; Sun, Chunyang; Hu, Zongfeng; Li, Xiaopeng.

Afiliação

Xie X; School of Pharmacy, Yantai University, Yantai Shandong 264005, China.
Lv J; School of Pharmacy, Yantai University, Yantai Shandong 264005, China.
Zhu W; School of Pharmacy, Yantai University, Yantai Shandong 264005, China.
Tian C; Beijing WellGene Company, Ltd, Beijing 100085, China.
Li J; School of Pharmacy, Yantai University, Yantai Shandong 264005, China; Beijing WellGene Company, Ltd, Beijing 100085, China.
Liu J; Beijing WellGene Company, Ltd, Beijing 100085, China.
Zhou H; Beijing WellGene Company, Ltd, Beijing 100085, China.
Sun C; Beijing WellGene Company, Ltd, Beijing 100085, China.
Hu Z; School of Pharmacy, Yantai University, Yantai Shandong 264005, China.
Li X; School of Pharmacy, Yantai University, Yantai Shandong 264005, China; Beijing WellGene Company, Ltd, Beijing 100085, China. Electronic address: patricklee@genevec.com.

Transl Oncol ; 15(1): 101287, 2022 Jan.

Article em En | MEDLINE | ID: mdl-34808461

Palavras-chave

Cancer immunotherapy; HSV-1; IL-12; Oncolytic virus; PD-1 antibody

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google